Britain and America have secured a significant commercial pact that will preserve zero duties on UK pharmaceutical products being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the public health system. This commitment secures that duties on these crucial goods will stay at nothing for a period of three years.
This agreement comes after previous warnings to dramatically increase duties on patented pharmaceutical imports, with figures floated reaching one hundred percent.
"This deal between the UK strengthens the worldwide climate for new treatments and brings much-needed equity to transatlantic pharmaceutical trade," a statement said.
Economic Significance
Pharmaceuticals are one of the UK's biggest exports to the US, which is clearly the biggest market for large companies like GSK and AstraZeneca.
Trade data indicate that in the year to the end of September, the UK sold medicines worth £11.1bn to the US. This value accounted for 17.4% of British export trade in that period.
"This guarantee secures employment, stimulates investment and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Detailed UK Commitments
The pact involves several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to increase overall health service expenditure on medicines from 0.3% of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The amount manufacturers must return to the NHS to control costs will be restricted at 15%. Last year, repayments were more than twenty percent.
Recent Tensions
The deal comes amid a long-running tension between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that US consumers were paying significantly more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been delayed or cancelled, while substantial funding commitments have been directed toward American operations.
The Science Minister stated that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had decreased as a share of its total funding over the previous ten-year period.
